Department of Laboratory Medicine, Chungbuk National University Hospital, Cheongju, Republic of Korea.
Department of Laboratory Medicine, Chungbuk National University College of Medicine, Cheongju, Republic of Korea.
Acta Haematol. 2019;142(4):239-243. doi: 10.1159/000499523. Epub 2019 May 27.
Acquired amegakaryocytic thrombocytopenia (AAMT) is a rare disease that causes severe bleeding. The pathogenesis and treatment of AAMT have not yet been defined. We report the case of a 60-year-old woman diagnosed with AAMT, who presented with severe thrombocytopenia, gastroin-testinal bleeding, and significantly reduced bone marrow megakaryocytes. The patient was treated with methylprednisolone, cyclosporin, and intravenous immunoglobulin. After 2 weeks of treatment, her platelet count started to increase, and her bone marrow megakaryocyte count had normalized 3 months after diagnosis. At the time of diagnosis, the patient was seropositive for anti-c-mpl antibody but was seen to be seronegative once the platelet count recovered. In contrast, anti-c-mpl antibodies were not detected in the serum of 3 patients with idiopathic thrombocytopenic purpura. This case study suggests that anti-c-mpl antibody plays an important role in the development of AAMT, and that intensive immunosuppressive treatment is required for autoantibody clearance and recovery of megakaryocyte count.
获得性巨核细胞血小板减少症(AAMT)是一种罕见的疾病,可导致严重出血。AAMT 的发病机制和治疗尚未明确。我们报告了一例 60 岁女性 AAMT 病例,该患者表现为严重血小板减少、胃肠道出血和骨髓巨核细胞明显减少。该患者接受了甲基强的松龙、环孢素和静脉注射免疫球蛋白治疗。治疗 2 周后,患者的血小板计数开始升高,诊断后 3 个月骨髓巨核细胞计数恢复正常。诊断时,患者抗 c-mpl 抗体呈阳性,但血小板计数恢复后呈阴性。相比之下,3 例特发性血小板减少性紫癜患者的血清中未检测到抗 c-mpl 抗体。本病例研究提示抗 c-mpl 抗体在 AAMT 的发病机制中起重要作用,需要强化免疫抑制治疗以清除自身抗体并恢复巨核细胞计数。